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Abstract
Background: Dominant mutations in Cu/Zn-superoxide dismutase (SOD1) gene cause a familial form of amyotrophic
lateral sclerosis (SOD1-ALS) with accumulation of misfolded SOD1 proteins as intracellular inclusions in spinal motor
neurons. Oligomerization of SOD1 via abnormal disulfide crosslinks has been proposed as one of the misfolding
pathways occurring in mutant SOD1; however, the pathological relevance of such oligomerization in the SOD1-ALS
cases still remains obscure.
Methods: We prepared antibodies exclusively recognizing the SOD1 oligomers cross-linked via disulfide bonds in vitro.
By using those antibodies, immunohistochemical examination and ELISA were mainly performed on the tissue samples
of transgenic mice expressing mutant SOD1 proteins and also of human SOD1-ALS cases.
Results: We showed the recognition specificity of our antibodies exclusively toward the disulfide-crosslinked SOD1
oligomers by ELISA using various forms of purified SOD1 proteins in conformationally distinct states in vitro.
Furthermore, the epitope of those antibodies was buried and inaccessible in the natively folded structure of
SOD1. The antibodies were then found to specifically detect the pathological SOD1 species in the spinal motor
neurons of the SOD1-ALS patients as well as the transgenic model mice.
Conclusions: Our findings here suggest that the SOD1 oligomerization through the disulfide-crosslinking associates
with exposure of the SOD1 structural interior and is a pathological process occurring in the SOD1-ALS cases.
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Background
Amyotrophic lateral sclerosis (ALS) is a neurodegenera-
tive disease, which associates with loss of motor neurons
in the affected nervous tissues including motor cortex,
brainstem, and spinal cords [1]. After several years of
disease onset, significant weakness of muscles is usually
followed by death due to the failure in respiratory
system. While most of the ALS cases are sporadic,
dominant mutations in Cu/Zn-superoxide dismutase
(SOD1) gene have been shown to cause familial forms
of ALS (SOD1-ALS) [2]. More than 150 types of
pathogenic mutations in SOD1 gene have been identified
[3], but importantly, no ALS-like phenotypes were con-
firmed in SOD1-knockout mice [4]. SOD1 is hence con-
sidered to gain toxic properties by pathogenic mutations.
A common pathological hallmark in SOD1-ALS cases is
the abnormal accumulation of mutant SOD1 proteins in
motor neurons of affected nervous tissues [5]. Pathogenic
mutations have hence been proposed to facilitate “mis-
folding” of SOD1 into abnormal conformation(s) and
thereby exert toxicities causing the disease.
SOD1 is a homodimeric metalloprotein that binds
copper and zinc ions and also forms an intramolecular
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disulfide bond [6]. A folded conformation of enzymati-
cally active SOD1 is significantly stabilized through the
metal binding and the disulfide formation [7]. Indeed,
dissociation of metal ions and reduction of the disulfide
bond are known to decrease the conformational stability
of SOD1 and thereby facilitate its misfolding in vitro; for
example, demetallated (apo) SOD1 forms cross-linked
oligomers through the shuffling of the disulfide bond
[8], and further reduction of the disulfide bond in apo-
SOD1 leads to the formation of the amyloid-like fibrillar
aggregates [9]. Abnormal SOD1 trimers have also been
recently shown to form in vitro at acidic pH and exhibit
toxicities toward cultured cells [10]. Moreover, the struc-
tural dynamics of immature SOD1 has been extensively
characterized in the atomic level [11–13]. Increasing
numbers of recent in vitro studies have revealed various
misfolding pathways of SOD1 proteins; however, it still
remains obscure how SOD1 changes its conformation
under the pathological conditions in vivo.
Actually, quite limited information is available on the
biochemical/structural properties of pathological SOD1
species in human SOD1-ALS cases, partly because most
of the motor neurons, which are the most affected cell
types in ALS, are usually lost at autopsies. Therefore,
any changes of SOD1 occurring specifically in affected
motor neurons could not become evident in the bio-
chemical experiments using the homogenates of spinal
cords. Nonetheless, in transgenic ALS-model mice over-
expressing mutant SOD1, the enzymatic activation of
SOD1 has been shown to be retarded in spinal cords but
not in the control tissues such as kidney and liver [14].
In other words, immature forms of SOD1 are expected
to accumulate specifically in the spinal cord as misfolded
proteins. Actually, the amyloid-like aggregates, which are
composed of SOD1 lacking the disulfide bond, have
been detected in the spinal motor neurons of transgenic
ALS-model mice [15], while there has been no evidence
to support the formation of amyloid-like aggregates in
human SOD1-ALS cases [16]. Alternatively, we have pre-
viously detected the disulfide-crosslinked SOD1 oligomers
in the spinal cord but not in the liver of ALS-model mice
[17]. Pathological roles of the disulfide-crosslinked oligo-
mers have been examined mainly in cultured cells [18, 19]
but still remain less characterized in the transgenic mice
and also in human SOD1-ALS cases.
In this study, we prepared and characterized the anti-
bodies recognizing the disulfide-crosslinked SOD1 oligo-
mers in vitro to test their pathological relevance in
SOD1-ALS. Compared to the previous studies, we have
more extensively examined the reactivity of our antibodies
against purified SOD1 proteins in various metallation/di-
sulfide states and ensured the recognition specificities of
our antibodies to the disulfide-crosslinked SOD1 olig-
omers. In the ALS-model mice, the immunoreactivities
with our antibodies were evident from their pre-
symptomatic stage and also specifically in their spinal cords.
More importantly, the immunoreactivities with our anti-
bodies were detected in spinal motor neurons of the human
SOD1-ALS cases. We thus propose that the disulfide-
crosslinked SOD1 oligomers possess an immunological
epitope selective for the SOD1 species with abnormal con-
formations occurring in the pathological conditions.
Methods
Protein preparation and purification
Introduction of mutations was performed by an Inverse
PCR method using a KOD-FX-neo DNA polymerase
(TOYOBO) and confirmed by DNA sequencing. Escheri-
chia coli SHuffle™ (NEB) was transformed with a pET-15b
plasmid (Novagen) containing cDNA of human SOD1,
and the protein expression was induced in the shaking
culture with 0.1 mM isopropyl β-D-1-thiogalactopyrano-
side (IPTG) at 20 °C for 20 h. Cells were lysed with ultra-
sonication in PBS containing 2% Triton X-100, DNase I,
and MgSO4, and the supernatant after centrifugation at
20,000 x g for 15 min. was loaded on a HisTrap HP col-
umn (1 mL, GE Healthcare). SOD1 proteins were eluted
with a buffer containing 50 mM sodium phosphate
(Na-Pi), 100 mM NaCl, and 250 mM imidazole at
pH 7.0. Metal ions bound to SOD1 proteins were removed
by two-step dialysis first against a buffer containing 50 mM
sodium acetate, 100 mM NaCl, and 10 mM EDTA at
pH 4.0 at 4 °C for 16 h and then against a buffer containing
100 mM Na-Pi, 100 mM NaCl, and 5 mM EDTA at
pH 7.4 (called NNE buffer). The proteins were treated with
thrombin (GE Healthcare) to remove an N-terminal His-
tag and further purified by size-exclusion chromatography
using a Cosmosil 5Diol-300-II column (nacalai tesque).
For the epitope mapping of antibodies, we have pre-
pared the following eight peptides as a fusion protein
with glutathione-S-transferase, which was further N-
terminally tagged with a 6 x His tag: Ala 1 – Lys 23
(Pepexon1), Glu 24 – Ala 55 (Pepexon2), Gly 56 – Arg 79
(Pepexon3), His 80 – Val 118 (Pepexon4), Val 119 – Gln
153 (Pepexon5), Glu 24 – His 43 (Pep1), Ser 34 – Asn 53
(Pep2), and Gly 44 – His 63 (Pep3). All of those fusion
proteins were overexpressed in E. coli BL21(DE3) with
shaking at 20 °C for 20 h in the presence of 0.1 mM
IPTG. As described above, the cells were lysed, and the
fusion proteins were purified from the soluble super-
natant with a HisTrap HP column.
Preparation and purification of anti-SOD1olig antibody
Demetallated SOD1 with A4V mutation as purified
above (5 mg/mL) was incubated in the NNE buffer at
37 °C for five days, by which soluble SOD1(A4V) oligo-
mers were prepared. Those SOD1(A4V) oligomers were
emulsified with either complete Freund's adjuvant
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(DIFCO) in the initial injection or incomplete Freund's
adjuvant and injected subcutaneously into a female New
Zealand White rabbit at intervals of 2 – 4 weeks. Antisera
were sampled at two weeks after the fifth or sixth injection,
and immunoglobulins specific to antigen were affinity-
purified using CNBr-activated Sepharose 4B (GE Health-
care) conjugated with the SOD1(A4V) oligomers.
To isolate the antibodies recognizing SOD1 oligomers
but not the folded proteins, the affinity-purified immu-
noglobulins were washed with Ni2+-affinity resins that
bind His-tagged wild-type SOD1S-S proteins (SOD1-
resins). SOD1-resins were prepared by adding 100 μL of
His-SELECT nickel affinity gel (Sigma) to 500 μL of
200 μM His-tagged wild-type SOD1S-S in a buffer con-
taining 50 mM Tris and 100 mM NaCl at pH 7.4 and in-
cubated at 4 °C for an hour. The resins were washed
with PBS and then incubated with the affinity-purified
immunoglobulins in PBS with rotation at 4 °C for an
hour. The resins were spun down, and again, the freshly
prepared SOD1-resins were added to the supernatant
and rotated at 4 °C for an hour. After repeating this ab-
sorption procedure four times, Ni2+-affinity resins were
added to the supernatant in order to remove His-tagged
SOD1 proteins detached from the SOD1-resins. Concen-
trations of purified antibodies were then determined by
Micro BCA Protein Assay kit (Thermo).
Preparation and purification of anti-SOD1int antibody
Production of a polyclonal antibody to a peptide of SOD1
(Gly 44 – Asn 53) was performed by Eurofins Genomics.
Briefly, the peptide, H2N-CG
44FHVHEFGDN53-COOH,
was conjugated through its N-terminal Cys with keyhole
limpet hemocyanin, with which a rabbit was immunized
in the 42-day protocol. The sera were then purified using
a Sulfo-Link Coupling Resin (Thermo) with the peptide,
Gly 44 – Asn 53, Gly 44 – Glu 49, His 46 – Gly 51, or His
48 – Asn 53, by which anti-SOD144–53, anti-SOD144–49,
anti-SOD146–51, or anti-SOD148–53 antibody was purified,
respectively. All of the peptides have an additional Cys
residue at the N-terminus for its conjugation with the
resin. For preparation of anti-SOD1int antibody, anti-
SOD144–53 antibody was first loaded on a Sulfo-Link
Coupling Resin (Thermo) cross-linked with purified apo-
SOD1S-S proteins, and the flow-through fraction was col-
lected, concentrated, and then purified using a Sulfo-Link
resin conjugated with a His 48 – Asn 53 peptide. Concen-
trations of purified antibodies were determined by Micro
BCA Protein Assay kit (Thermo).
Enzyme-linked immunosorbent assay (ELISA)
To prevent adventitious binding of contaminant metal
ions to SOD1 proteins in ELISA, we used Tris-buffered
saline (TBS) that was treated with Chelex® 100 Resin
(Bio-Rad). For the assay of E,E-SOD1 proteins, a strong
chelator for divalent metal ions, EDTA (5 mM), was fur-
ther included in TBS, by which an artificial supply of di-
valent metal ions (zinc ions, in particular) from buffers
could be prevented. SOD1 variants with distinct metalla-
tion and thiol-disulfide status (5 μg/well) were coated on
96-well plates (Nunc-Immuno™ Plate CII, Thermo) over-
night at 4 °C. After three washes with TBS containing
0.05% (v/v) Tween 20 (TBS-T), the plates were blocked
with TBS containing 0.5% (w/v) BSA for an hour at
room temperature. After six washes with TBS-T, either
antibody purified in this study, polyclonal anti-human
SOD1 (FL-154, Santa Cruz Biotechnology), USOD
(#SPC-205, StressMarq Bioscience), or SEDI (#SPC-206,
StressMarq Bioscience) antibody was added as a primary
antibody (0.2 μg/mL) and incubated for an hour at room
temperature, which was then followed by secondary
antibody with horseradish peroxidase (goat anti-rabbit
IgG, 1:1,000; Thermo Scientific) for an hour at room
temperature. As the substrate solution, O-phenylenedi-
amine and 0.012% H2O2 in a buffer containing 100 mM
sodium citrate at pH 5.0 were used. The absorbance was
read at 490 nm using a plate reader (Epoch, BioTek).
For sandwich ELISA, a plate (Nunc-Immuno™ Plate
CII, Thermo) was coated with the capture antibodies
(0.2 μg/mL anti-SOD1int or 0.02 μg/mL anti-SOD1
(FL-154, Santa Cruz Biotechnology) antibodies) over-
night at 4 °C and blocked with 1% BSA for an hour. Sol-
uble extracts of the tissue samples containing 10 μg of
total proteins were then applied and incubated at room
temperature for an hour. The captured SOD1 proteins
were detected by sheep anti-SOD1 (1:2,000, Calbiochem)
and HRP-conjugated rabbit anti-sheep (1:1,000, Bio-Rad)
antibodies as the detection and secondary antibodies, re-
spectively. As the substrate solution, O-phenylenediamine
and 0.012% H2O2 in a buffer containing 100 mM sodium
citrate at pH 5.0 were used. The absorbance was read at
490 nm using a plate reader (Epoch, BioTek).
Transgenic mice
Transgenic mice carrying human SOD1 gene with
G93A mutation (B6.Cg-Tg(SOD1*G93A)1Gur/J in a
C57BL/6 background) and human wild-type SOD1 gene
(B6.Cg-Tg(SOD1)2Gur) were purchased from Jackson
Laboratory (Bar Harbor, ME) and maintained heterozy-
gous with a C57BL/6 background. Mice expressing hu-
man SOD1 with G37R were described previously [20].
Mice were genotyped for human SOD1 using tail DNA
as described previously [21]. All experiments were
reviewed and approved by the Animal Use and Care
Committees of Keio University and Nagoya University,
and care was taken to minimize suffering and limit the
number of animals used.
Mice were deeply anesthetized with sodium pentobar-
bital and then perfused via the aortic cone with PBS,
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followed by 4% paraformaldehyde in a buffer containing
0.1 M Na-Pi at pH 7.4. The lumbar region of each spinal
cord (ca. 2 cm) was removed and post-fixed in the same
fixative overnight at 4 °C, after which it was immersed in
20% sucrose in 0.1 M Na-Pi, pH 7.4, overnight at 4 °C.
The tissue was then frozen in OCT compound (Sakura
Finetek) and sectioned at 40 μm on a cryostat. Rabbit
anti-SOD1olig (0.02 μg/mL) and mouse monoclonal anti-
human SOD1 (0.02 μg/mL, clone 1G2, MBL) antibodies
were used for immunohistochemistry as a primary anti-
body, and biotinylated anti-mouse IgG (H + L) (1:200 dilu-
tion, Vector Laboratories, Inc.) was used as a secondary
antibody. The immunoreaction was amplified using the
VECTASTAIN ABC HRP Kit (Vector Laboratories, Inc.)
according to the manufacturer’s direction. The free-
floating sections were processed using diaminobenzidine
(DAB) as the chromogen followed by counter-staining
with hematoxylin [22]. Stained sections were then exam-
ined using a microscope (BX51, Olympus).
Human cases
The human cases examined in this study included three
SOD1-ALS cases with C111Y mutation, four sporadic
ALS cases with TDP-43-positive inclusions (negative for
SOD1 mutations), and three non-ALS controls. All tissues
from ALS patients and non-ALS controls were obtained
by autopsy with informed consent at Matsumoto Medical
Center in Japan, and information on the cases was sum-
marized in Additional file 1: Table S1. The collection of
tissues and their use in this study were approved by the in-
stitutional review board for research ethics of Matsumoto
Medical Center and Keio University, Japan.
For immunohistochemical examination, the spinal cord
was fixed in 10% buffered formalin, and multiple tissue
blocks were embedded in paraffin. Deparaffinized 4-μm-
thick sections were immunostained by the streptavidin-
biotin method using rabbit anti-SOD1olig (0.02 μg/mL),
rabbit anti-SOD1int (0.3 μg/mL), mouse monoclonal anti-
human SOD1 (0.5 μg/mL, clone 1G2, MBL) antibodies,
and the corresponding biotin-conjugated secondary anti-
bodies. The sections were processed with HRP-conjugated
streptavidin and DAB as the chromogen and further
stained for nuclei with hematoxylin. For double immuno-
fluorescence, deparaffinized sections were first incubated
with Sudan Black B to suppress auto-fluorescence and
then stained with the primary antibodies followed by the
corresponding FITC- or Cy3-labeled secondary antibodies
(Jackson Labs, Pittsburgh, PA).
Sample preparations for biochemical analysis on human
and mouse tissues
For human cases, the ventral and dorsal horns were sep-
arately excised from the frozen thoractic spinal cord
samples. Frozen mice tissues (lumbar spinal cord,
cervical spinal cord, cerebellum, and brainstem) were
also separately prepared. The tissues were then homoge-
nized and ultrasonicated in PBS containing 1% NP-40,
100 mM iodoacetamide, 5 mM EDTA, and EDTA-free
Complete Protease inhibitor cocktail (Roche). The ho-
mogenates were centrifuged (20,000 x g, 30 min. 4 °C) to
prepare the soluble supernatants and then examined for
their total protein concentrations by using Micro BCA
Assay Kit (Thermo Scientific).
Western blotting analysis
Soluble proteins in the tissue extracts (15 μg/lane) were
separated using 12.5% polyacrylamide gels and blotted
onto a PVDF membrane (0.2 μm, Wako). The mem-
brane was treated with a blocking solution containing
5% (w/v) dried milk and 0.01% (v/v) Tween 20 in PBS at
pH 7.4. The blots were probed with rabbit anti-SOD1
antibody (1:10,000; FL-154, Santa Cruz Biotechnology)
and HRP-conjugated goat anti-rabbit IgG antibody
(1:10,000; Thermo Scientific), visualized using Immu-
noStar LD (Wako), and then observed in the LumiCube
(Liponics). To validate an equal loading of tissue extracts,
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was
used as an internal marker. The membranes were treated
with the WB Stripping Solution (nacalai tesque) for 1 h at
37 °C and reprobed with rabbit anti-GAPDH antibody
(1:5,000; FL-335, Santa Cruz Biotechnology).
Statistics
All statistical tests were performed using Statcel 3 soft-
ware (OMS Publishing Inc.). After the determination of
normality, multiple group comparisons were performed
using a one-way ANOVA followed by the Tukey–Kramer
post-hoc test.
Results
Preparation of soluble and disulfide-crosslinked oligomers
of SOD1 in vitro
Among four Cys residues (Cys 6, 57, 111, and 146) in
SOD1, the conserved disulfide bond forms between Cys
57 and 146 within an SOD1 molecule and significantly
contributes to structural stabilization of a SOD1 protein
[7]. Under destabilizing conditions in vitro, however, the
disulfide bond of SOD1 is shuffled among the four Cys
residues in inter- as well as intra-molecular fashion,
resulting in the formation of SOD1 oligomers cross-
linked via disulfide bond(s) [8]. In this study, an apo and
disulfide form of SOD1 (E,E-SOD1S-S; the first and sec-
ond E mean empty at copper and zinc sites, respectively;
thiol-disulfide status is indicated as superscript.) (Fig. 1a)
was first prepared and then incubated at 37 °C for five
days without any agitation. SOD1 with ALS-causing mu-
tations formed the high-molecular weight species, which
remained in supernatant after centrifugation at 20,000 x g
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and were observed in non-reducing but not in reducing
SDS-PAGE (Additional file 2: Figure S1). These results
confirm the formation of the soluble SOD1 oligomers
cross-linked via disulfide bonds.
Purification of an antibody recognizing the disulfide-
crosslinked SOD1 oligomers
A rabbit was first immunized with the soluble and
disulfide-crosslinked oligomers of A4V-mutant SOD1 pre-
pared in vitro, and then the polyclonal antibodies were
affinity-purified using those oligomers. Nonetheless, the
purified antibody was not selective to the oligomers; a na-
tively folded SOD1 protein (Cu,Zn-SOD1S-S) significantly
reacted with the antibody (data not shown). To increase
the specificity of antibodies to the oligomers, the purified
antibodies were washed with Ni2+-affinity resins on which
wild-type SOD1S-S was immobilized through its N-
terminal His tag (see Methods). As shown in Fig. 1b and c,
the finally purified antibody (called anti-SOD1olig antibody)
exhibited significantly higher ELISA signals to the soluble
disulfide-crosslinked SOD1(A4V) oligomer than those to
wild-type (WT) and A4V-mutant E,E-SOD1S-S pro-
teins (P < 0.01). It is also important to note that anti-
SOD1olig antibody can recognize the soluble and
disulfide-crosslinked oligomers of G37R-mutant SOD1
but not E,E-SOD1(G37R)S-S (P < 0.01: Fig. 1b and c). Our
anti-SOD1olig antibody was hence found to exclusively
recognize the soluble and disulfide-crosslinked SOD1
oligomers.
Immunohistochemical detection of pathological SOD1
species by anti-SOD1olig antibody
We previously detected the disulfide-crosslinked SOD1
species by isolating those from the spinal cord homoge-
nates of ALS-model mice [17, 23]. In this study, we
attempted to probe the disulfide-crosslinked oligomers
during the pathogenesis of SOD1-ALS by using our anti-
SOD1olig antibody. For that purpose, the ALS-model
mice expressing human SOD1 with G93A mutation
(G1H mice) on a congenic C57BL/6 background were
immunohistochemically examined. As shown in Fig. 2a
and b, the species immunoreactive to anti-SOD1olig anti-
body were observed in the ventral horn of the lumbar
spinal cord before the disease onset (at 60 and 100 days
of age). No staining with anti-SOD1olig antibody was
confirmed in the corresponding area of spinal cords of a
non-transgenic mouse (Additional file 3: Figure S2A and
B). Also, when anti-SOD1olig antibody was pre-absorbed
with the disulfide-crosslinked oligomers of A4V-mutant
SOD1, any immunoreactive species were not observed in
the spinal cord of a G1H mouse (100 days) (Additional file
3: Figure S2C). Instead, when pre-adsorbed with E,Zn-
SOD1(A4V)S-S, anti-SOD1olig antibody was able to detect
the immunoreactive species in the spinal cord of a G1H
a b c
Fig. 1 Anti-SOD1olig antibody recognizes soluble SOD1 oligomers with the disulfide crosslinks but not folded SOD1 in vitro. (a) Description of
SOD1 in distinct metallation and thiol-disulfide states. E,Zn-SOD1S-S, in which SOD1 with the disulfide bond binds a zinc ion at the Zn-binding site, is
shown as an example. (b) Specificity of purified anti-SOD1olig antibody was examined by indirect ELISA using E,E-SOD1S-S proteins (WT, A4V, G37R) and
soluble disulfide-crosslinked oligomers (A4V, G37R). (c) No statistically significant difference in the amounts of SOD1 proteins adsorbed on
wells was confirmed by ELISA using anti-SOD1 antibody (FL-154, Santa Cruz Biotechnology). The ELISA signal was represented as a ratio against
that obtained using bovine serum albumin (BSA). Three independent experiments were performed to estimate error bars (standard deviation)
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mouse (100 days) (Additional file 3: Figure S2D). These
control experiments assure the specificity of anti-SOD1olig
antibody toward the pathological SOD1 species in the
transgenic mice.
At the end stage of the disease (140 and 160 days of
age), however, immunostaining with anti-SOD1olig anti-
body was significantly reduced in the lumbar spinal cord
of G1H mice (Fig. 2c and d),. This was not described by
the changes in total amounts of soluble SOD1 in the
lumbar spinal cord, which was actually increased during
aging ([14]; also see below). We previously showed that
the number of the ChAT-positive motor neurons at
140 days of age was reduced down to one third of those
at 60 days of age in G1H mice [24]. The reduced immu-
nostaining with anti-SOD1olig antibody might thus indi-
cate loss of motor neurons at the disease end-stage.
Nonetheless, mutant SOD1 has been also known to ac-





Fig. 2 Immunohistochemical examination on G1H mice with anti-SOD1olig antibody. The sections of lumbar spinal cords (ventral horn) of G1H
mice at a 60, b 100, c 140, and d 160 days of age were stained with anti-SOD1olig antibody. The images in the low magnification are shown in
the left panel, where the region enclosed with a broken line is magnified and shown in the right panel. Nuclei were counterstained with
hematoxylin (blue). The bar in each panel represents 100 μm (left panel) and 50 μm (right panel)
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of diseased G1H mice [25]. Actually, the diffuse staining of
SOD1 was observed in the lumbar spinal cord of pre-
symptomatic G1H mice (60 and 100 days of age), and the
SOD1-positive inclusions became evident in the disease
end-stage (140 and 160 days of age) (Additional file 4:
Figure S3). Our anti-SOD1olig antibody is hence ex-
pected to have little immunoreactivity toward the SOD1-
positive inclusions formed in terminally ill G1H mice.
Based upon these results, we suggest that anti-SOD1olig
antibody specifically detects the pathological SOD1 spe-
cies occurring in the lumbar spinal cords of the pre-
symptomatic G1H mice.
By using anti-SOD1olig antibody, we have further per-
formed immunohistochemical examination on the spinal
cords of two SOD1-ALS cases with C111Y mutation. Two
cases (III-5 and IV-6 reported in [26]; Additional file 1:
Table S1) examined here had the disease duration of 1.2
and 4.0 years, respectively. It has been reported that
SOD1-positive inclusions are observed at the cytoplasm
and neurites of spinal motor neurons in those SOD1-ALS
cases with C111Y mutation [27]. Unlike G1H mice, those
SOD1-positive inclusions in the spinal cord of the case
IV-6 were immunostained with anti-SOD1olig antibody
(Fig. 3a). In the other SOD1-ALS case, III-5, almost no
motor neurons were spared due to the intense degener-
ation of the spinal cord, but sparse immunostaining by
anti-SOD1olig antibody was confirmed in the remaining
motor neurons of the cervical spinal cord (Fig. 3b). The
pathological inclusions in the spinal motor neurons were
co-immunostained by anti-SOD1 and anti-SOD1olig
antibodies (Fig. 3c-f ), and no immunostaining with
anti-SOD1olig antibody was confirmed in non-ALS
cases (Additional file 5: Figure S4A). Accordingly,
anti-SOD1olig antibody can specifically detect the SOD1
species accumulated as pathological inclusions in spinal
motor neurons of SOD1-ALS patients. This appeared to
contradict with the declined immunostaining with anti-
SOD1olig antibody in the end stage G1H mice (Fig. 2c and
d) but actually support the previous reports describing dis-
tinct properties of SOD1-positive inclusions between trans-
genic mice and human cases [15, 16] (also see Discussion).
These results show that our anti-SOD1olig antibody for
the disulfide-crosslinked oligomers was able to detect
pathological SOD1 species, but a major concern in the
preparation of this antibody is a quite low yield (7.5 mL of
0.2 μg/mL antibody from one immunized rabbit) after sev-
eral purification procedures. Actually, we have little
amounts of anti-SOD1olig antibody left, and constant
reproduction of anti-SOD1olig antibody would also be
quite difficult due to its polyclonal nature. To deal with
those troubles on anti-SOD1olig antibody, we attempted to
first determine the epitope of anti-SOD1olig antibody and
then produce another oligomer-specific antibody by im-
munizing rabbits with the peptide covering that epitope.
Anti-SOD1olig antibody recognizes interior of the SOD1
folded structure
The epitope mapping of anti-SOD1olig antibody was per-
formed by ELISA using five peptides, Pepexon1–5, each of
which corresponds to a translated product of five exons
a
c d e f
b
Fig. 3 Immunohistochemical examination of human SOD1-ALS cases (C111Y mutation) with anti-SOD1olig antibody. DAB staining of a a sacral
spinal cord (ventral horn) section of the case IV-6 and b a cervical spinal cord (ventral horn) of the case III-5 was performed using anti-SOD1olig
antibody. c-f Serial sections of a lumbar spinal cord (ventral horn) of the case IV-6 were immunostained with c, e anti-SOD1olig and d, f
anti-SOD1 (clone 1G2, MBL) antibodies. Sections shown in c and d or e and f are serial. Nuclei were also stained by hematoxylin (blue).
The bars represent 50 μm
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in a SOD1 gene (Fig. 4a). As shown in the upper panel of
Fig. 4b, ELISA signals of anti-SOD1olig antibody were ob-
served exclusively in Pepexon2, suggesting that the antibody
recognizes the region between Glu 24 and Ala 55 in SOD1.
To further narrow down the epitope region recognized by
anti-SOD1olig antibody, Pepexon2 was dissected into three
peptides, Pep1 – 3 (Fig. 4a), and again examined by ELISA.
Pep2 and 3 but not Pep1 gave rise to ELISA signals (the
lower panel of Fig. 4b), indicating that anti-SOD1olig anti-
body recognized the region overlapped between Pep2 and
Pep3, i.e. from Gly 44 to Asn 53. Quite interestingly, the
epitope (Gly 44 – Asn 53) is buried in the folded structure
of SOD1 (Fig. 4c), which is consistent with almost no re-
activity of anti-SOD1olig antibody toward folded SOD1 pro-
teins (Fig. 1b). These results thus show that the buried
region from Gly 44 to Asn 53 becomes exposed upon for-
mation of the disulfide-crosslinked SOD1 oligomers.
Antibody recognizing the structural interior of SOD1
exhibits the specificity to the disulfide-crosslinked
oligomers
Polyclonal antibodies were then generated by immuniz-
ing a rabbit with the Gly 44 - Asn 53 peptide (Fig. 4c)
and affinity-purified using the same peptide. The resultant
antibody (anti-SOD144–53) was found to exhibit the in-
creased immunoreactivity to the soluble and disulfide-
crosslinked oligomers over the folded Cu,Zn-SOD1(WT)S-S
and E,E-SOD1(A4V)S-S (Fig. 5a and Additional file 6: Figure
S5A). We then attempted to increase the specificity of the
antibody to the oligomers by further affinity-purification
with Gly 44 - Glu 49, His 46 - Gly 51, and His 48 - Asn 53
peptides and prepare anti-SOD144–49, anti-SOD146–51, and
anti-SOD148–53 antibody, respectively; however, the specifi-
city to the oligomers was not significantly improved in
those three antibody fractions (Fig. 5a, w/o absorption).
The antisera were, therefore, first absorbed with His-tagged
SOD1(WT)S-S on Ni2+-affinity resins and then affinity-
purified with the peptides (44–49, 46–51, and 48–53)
covalently immobilized on Sulfo-Link resins. As shown
in Fig. 5a (w/ absorption), such an additional absorp-
tion procedure was found to increase the specificity of
anti-SOD148–53 antibody to the soluble and disulfide-
crosslinked oligomers of A4V-mutant SOD1. We hence
call this fraction of anti-SOD148–53 as anti-SOD1int
antibody in the following section. The yield of anti-
SOD1int antibody was high (ca. 150 μg from 1 mL of
a
b c
Fig. 4 Anti-SOD1olig antibody reacts with the interior of SOD1 structure. a The translated products of five exons in SOD1 and the three peptides,
Pep 1, 2, and 3, are shown in schematic representation of the SOD1 primary structure. The ligands for copper and zinc ions are also shown and
colored blue and red, respectively. His 63 (colored green) is a ligand for bridging both copper and zinc ions. b Identification of the epitope for
anti-SOD1olig antibody (filled bars) was performed by indirect ELISA using the dissected peptides of SOD1 shown in (a). The peptides were prepared as
a fusion protein with an N-terminal 6x His tagged GST. Almost equal amounts of peptides were examined, which was confirmed by ELISA using anti-
His tag antibody (sc-8036, Santa Cruz Biotechnology) (open bars). The ELISA signal was represented as a ratio against that obtained using BSA. c The
region covering the epitope of anti-SOD1olig antibody (Gly44 - Asn53) is shown red in the crystal structure of SOD1 (PDB ID: 2C9V). Copper (blue) and
zinc (orange) ions are also indicated with the ligands
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antisera) enough to conduct its biochemical and immu-
nochemical characterization.
To further check the specificity of our anti-SOD1int
antibody in vitro, we prepared various forms of WT and
ALS-mutant (A4V, G37R, and G85R) SOD1 proteins in-
cluding E,E-SOD1SH, E,E-SOD1S-S, E,Zn-SOD1SH, E,Zn-
SOD1S-S, Cu,E-SOD1S-S, Cu,Zn-SOD1S-S, and soluble
oligomers with disulfide crosslinks (see Fig. 1a). Insoluble
and amyloid-like SOD1 aggregates were also prepared by
shaking E,E-SOD1SH with 1,200 rpm at 37 °C [9]. Among
those, only the soluble and disulfide-crosslinked oligomers
but none of the others were recognized by anti-SOD1int
antibody (Fig. 5b and Additional file 6: Figure S5B). Based
upon these results in vitro, therefore, anti-SOD1int anti-
body can detect the disulfide-crosslinked SOD1 oligomers,
in which the protein interior is significantly exposed to
the solvent.
Actually, there are several precedents of the anti-
bodies recognizing the protein interior of SOD1,
which include USOD and SEDI polyclonal antibodies
raised against the peptides, GG-L42HGFHVH48-GG
and GG-R143LACGVIGI151-GG, respectively (also see
Discussion) [16, 28]. Unfortunately, canonical USOD
and SEDI antibodies reported by Chakrabartty and
co-workers were not available, but the polyclonal
antibodies raised against the same peptides as above
were commercially available. We thus characterized
those commercially available “USOD-like” and “SEDI-
like” antibodies; indeed, USOD-like and SEDI-like
antibodies were confirmed to specifically recognize
Pepexon2 and Pepexon5, respectively (Additional file 7:
Figure S6). As shown in Fig. 5c and d, USOD-like
and SEDI-like antibodies exhibited reactivities toward al-
most all states examined except wild-type SOD1S-S that is
fully or partially metallated and would thus be selective to
mutant SOD1 proteins. Nonetheless, the recognition spe-
cificity of our anti-SOD1int antibody toward the disulfide-
crosslinked oligomers was significantly higher than those
of USOD/SEDI-like antibodies (Fig. 5b, c and d). These
data thus emphasize the unprecedented recognition speci-






Fig. 5 Anti-SOD1int antibody exclusively recognizes soluble disulfide-crosslinked SOD1 oligomers in vitro. a The antibodies were tested for their
specific reactivities to soluble disulfide-crosslinked oligomers (black filled bars) over Cu,Zn-SOD1(WT)S-S (open bars) and E,E-SOD1(A4V)S-S (gray
filled bars) by indirect ELISA. Antisera were either affinity-purified with the corresponding peptides (w/o absorption) or first absorbed with SOD1(WT)S-S
and then affinity-purified with the peptides (w/ absorption). Anti-SOD148–53 antibody obtained after the absorption exclusively reacted with soluble
disulfide-crosslinked oligomers and called anti-SOD1int antibody. b-d The reactivities of b anti-SOD1int, c USOD-like, and d SEDI-like antibody were
examined with indirect ELISA. Several forms of SOD1 (WT, A4V, G37R, G85R) with a distinct metallation/disulfide status, soluble disulfide-crosslinked
oligomers and insoluble amyloid-like aggregates were prepared and fixed on an ELISA plate. The ELISA signal was represented as a ratio against that
obtained using BSA. Three independent experiments were performed to estimate error bars (standard deviation). Fixation of equal amounts of SOD1
proteins on each well of an ELISA plate was confirmed by ELISA using polyclonal anti-SOD1 antibody (FL-154, Santa Cruz Biotechnology),
which is shown in Additional file 6: Figure S5
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Disulfide-crosslinked SOD1 oligomers as an early
pathological species in spinal cords of ALS-model mice
To check the availability/specificity of anti-SOD1int anti-
body for the detection of pathological SOD1 in vivo, we
first examined the immunohistochemical analysis of
G1H mice as well as non-transgenic mice. Unfortunately,
however, the lumbar spinal cords of non-transgenic mice
were immunostained with anti-SOD1int antibody (data not
shown). This is in contrast to anti-SOD1olig antibody
showing no immunostaining in non-transgenic mice
(Additional file 3: Figure S2A and B). Those two anti-
bodies hence appear to have distinct specificities in the
immunohistochemical examination on mouse tissues.
Nonetheless, anti-SOD1int as well as anti-SOD1olig anti-
body can exclusively recognize disulfide-crosslinked
SOD1 oligomers in vitro in ELISA (Fig. 1b and 5b). We
thus further examined homogenates from model mice for
disulfide-crosslinked SOD1 oligomers by sandwich ELISA
with anti-SOD1int antibody.
Briefly, anti-SOD1int antibody was first fixed on the sur-
face of an ELISA plate and incubated with soluble frac-
tions of tissue homogenates. The SOD1 species captured
by the antibody were then detected with polyclonal anti-
SOD1 antibody followed by the corresponding secondary
antibody. Significant ELISA signals were observed in the
lumbar spinal cords of G1H mice from 30 to 140 days of
age (Fig. 6a, red circles) but not in those of non-transgenic
mice (Additional file 8: Figure S7A). Compared to G1H
mice, moreover, asymptomatic mice overexpressing wild-
type human SOD1 (WT mice) contained larger amounts
of total soluble SOD1 proteins but exhibited significantly
weaker signals with anti-SOD1int antibody (Additional
file 8: Figure S7A and B). We also observed that the
signals with anti-SOD1int antibody disappeared upon
pre-treatment of the spinal cord samples of G1H mice
with a reductant, dithiothreitol (DTT) (Additional file 8:
Figure S7C and D). These results thus suggest that anti-
SOD1int antibody detects disulfide-crosslinked SOD1 olig-
omers not only in in vitro protein samples but also in the
model mice in vivo.
It should also be noted in Fig. 6a (red circles) that the
ELISA signals from the lumbar spinal cords increase
from 30 to 140 days of age but significantly drop from
140 to 160 days of age (P < 0.01). The reduction in the
ELISA signals at 160 days of age was not described by
the changes in total amounts of soluble SOD1 in the
a c
b
Fig. 6 Anti-SOD1int antibody specifically detects pathological SOD1 in spinal cords of ALS-model mice. a, b SOD1 species recognized by a
anti-SOD1int and b anti-SOD1 (FL-154, Santa Cruz Biotechnology) antibody were quantified in the soluble fraction of the homogenates of lumbar
spinal cord (red), cervical spinal cord (green), brainstem (blue), and cerebellum (gray) of G1H mice by sandwich ELISA. Three independent mouse
samples at 30, 60, 100, 140, and 160 days of age were examined, and the averages were shown with error bars (standard deviation). ** (red and
green) represents the P value less than 0.01 versus the data on lumbar and cervical spinal cords at 30 days of age, respectively. c Soluble
disulfide-crosslinked SOD1 oligomers in mice were examined by Western blotting. Lumbar spinal cords of WT and G1H mice were homogenized
in the presence of 100 mM iodoacetamide and 1% NP-40 and centrifuged at 20,000 x g for 30 min so as to prepare soluble supernatant. In the
presence and absence of the reducing reagent, β-ME, the supernatant was then separated in a polyacrylamide gel by SDS-PAGE and probed by
Western blot using anti-SOD1 antibody (FL-154, Santa Cruz Biotechnology). GAPDH was used as a protein loading control for Western blot
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lumbar spinal cord (Fig. 6b, red circles). This is consistent
with the decreased anti-SOD1olig immunostaining of the
lumbar spinal cords of G1H mice at 140 and 160 days of
age (Fig. 2c and d, Additional file 4: Figure S3C and D),
while slightly different age-dependency in immunochemi-
cal response between anti-SOD1int and anti-SOD1olig
antibodies would reflect their distinct immunological
properties. As described later, however, the ELISA signals
with anti-SOD1int antibody did not decrease in the other
mouse model. The signal reduction in the disease end-
stage may thus be a phenomenon specific to the lumbar
spinal cord of G1H mice, but an exact reason for this re-
mains obscure. Instead, we would like to emphasize that
anti-SOD1int antibody can detect conformationally abnor-
mal SOD1 species in model mice with sandwich ELISA.
To test if SOD1s were oligomerized with disulfide
bonds in lumbar spinal cords of ALS-model mice, sol-
uble fractions of the lumbar spinal cord homogenates of
G1H mice were separated by non-reducing SDS-PAGE
and analyzed by Western blotting. Soluble and disulfide-
crosslinked SOD1 oligomers in vitro can be character-
ized by the reductant-sensitive smears in the high
molecular weight region in SDS-PAGE gels (Additional
file 2: Figure S1). As shown in Fig. 6c (left panel), smears
in the high molecular weight region (>50 kDa) were evi-
dent, albeit weak intensity, as early as 60 days of age in
G1H mice but not in WT mice (150 and 360 days) and
non-transgenic mice (100 days; data not shown). Also im-
portantly, those smears in G1H mice at 60 and 100 days
of age disappeared when the soluble fractions were treated
with β-mercaptoethanol (β-ME) prior to their loading on
an SDS-PAGE gel (Fig. 6c, right panel), supporting the for-
mation of disulfide-crosslinked SOD1 oligomers in the
ALS-model mice even before the disease onset.
After the disease onset (at 140 and 160 days of age), in
contrast, the reductant-sensitive SOD1 species in lumbar
spinal cords of G1H mice were observed as more dis-
tinct bands in the high molecular weight region
(>50 kDa, Fig. 6c). Also, even in the presence of β-ME,
some SOD1-positive species were stuck on top of the
separating gel. Therefore, we suppose different molecu-
lar properties of SOD1 oligomers between pre- and
post-symptomatic stages of G1H mice, which might de-
scribe significant reduction of the SOD1 species immu-
noreactive to anti-SOD1int antibody at 160 days of age
(Fig. 6a, red circles). Taken together, we speculate that
anti-SOD1int antibody specifically detects the disulfide-
crosslinked oligomers formed in the lumbar spinal cords
of G1H mice from their pre-symptomatic stages.
We also tested the tissue-specificity in the formation
of the disulfide-crosslinked oligomers; soluble superna-
tants from the homogenates of cervical spinal cord,
brainstem and cerebellum of G1H mice were examined
by sandwich ELISA using anti-SOD1int antibody. In ALS
cases, the lumbar spinal cord is mainly affected, but the
other regions of brains and spinal cords have also been
shown to be involved in the pathology [29]. In G1H mice,
the lumbar spinal cord is the most severely damaged, and
the changes occur later in the cervical spinal cords [30].
Some pathological changes are reported in the brainstem
[31], but the cerebellum is relatively spared [32]. As shown
in Fig. 6a, the ELISA signal intensities were significantly
weaker in cervical spinal cord, brainstem, and cerebellum
than those of lumbar spinal cord (P < 0.01 within the same
age group, except at 160 days of age); in particular, almost
no ELISA signals were observed in cerebellum. We con-
firmed similar levels of total SOD1 proteins among all of
those tissues (Fig. 6b). Also, no obvious smears in the high
molecular weight region were observed in the Western
blots of soluble fractions of the cerebellum, while the
brainstem lysates of G1H mice exhibited reductant-
sensitive smears at 160 days of age, albeit with weak inten-
sities (Additional file 9: Figure S8A and B). While toxic
SOD1 species might appear everywhere but only afflict
the spinal cord due to its vulnerability, amounts of SOD1
species probed with anti-SOD1int antibody were well cor-
related with the intensity of high-molecular-weight smears
in the Western blots and also the severity of the damages
in tissues (lumbar spinal cord > cervical spinal cord >
brainstem > cerebellum) of G1H mice.
We have also examined the ALS model mice expressing
human SOD1 with another mutation, G37R (loxG37R
mice) [20]. Compared to G1H mice, the expression level
of mutant SOD1 is lower, and the disease progression is
slower in loxG37R mice (the disease onset: ~350 days of
age). The sandwich ELISA showed the age-dependent in-
crease of the anti-SOD1int-positive SOD1 species in lum-
bar and cervical spinal cords but not in cerebellum of
loxG37R mice (Additional file 10: Figure S9A), while
amounts of the total soluble SOD1 remained almost con-
stant during aging in loxG37R mice (Additional file 10:
Figure S9B). When the spinal cord samples from loxG37R
mice were pre-treated with DTT, the ELISA signals with
anti-SOD1int antibody disappeared (data not shown). Fur-
thermore, Western blotting analysis on loxG37R mice re-
vealed the reductant-sensitive smears in lumbar spinal
cord (Additional file 10: Figure S9C), albeit with signifi-
cantly weaker intensities compared to those of G1H mice,
but not in cerebellum (Additional file 9: Figure S8C).
Taken together, these results suggest the formation of the
soluble disulfide-crosslinked SOD1 oligomers as patho-
logical changes also in loxG37R mice.
Anti-SOD1int antibody detects pathological SOD1 in
SOD1-ALS cases
To test the immunoreactivity of our anti-SOD1int anti-
body in human cases, the double immunofluorescence
staining with anti-SOD1int and anti-SOD1 antibodies
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was performed on the ventral horn of the lumbar spinal
cord section of the SOD1-ALS patients with C111Y mu-
tation (the case IV-6 in [26]; Additional file 1: Table S1).
As shown in Fig. 7a, abnormally accumulated SOD1
proteins in spinal motor neurons were immunostained
by anti-SOD1int antibody. Using serial sections of the
primary motor cortex (Fig. 7b), furthermore, the abnor-
mally accumulated SOD1 in cytoplasm and neurites of a
Betz cell were also immunostained by anti-SOD1int anti-
body. In another SOD1-ALS case with C111Y mutation
(the case III-4 in [26]; Additional file 1: Table S1), the




Fig. 7 Immunochemical detection of pathological SOD1 species in the SOD1-ALS cases with anti-SOD1int antibody. a Double immunofluores-
cence staining of the lumbar spinal cord section of the SOD1-ALS case with C111Y mutation (the case IV-6). The section was stained with rabbit
anti-SOD1int and mouse anti-SOD1 (clone 1G2, MBL) antibodies followed by Cy3-modified anti-rabbit (red) and FITC-modified anti-mouse (green)
secondary antibodies, respectively. A merged image (yellow) was also shown. b Serial sections of the primary motor cortex of the SOD1-ALS case
(the case IV-6) were immunostained with (left) anti-SOD1int and (right) anti-SOD1 (clone 1G2, MBL) antibodies and visualized with DAB staining.
c The lumbar spinal cord (ventral horn) of the case III-4, which exhibited exceptionally long disease duration (~69 years), was immunostained with
anti-SOD1int antibody. d, e SOD1 species recognized by d anti-SOD1int and e anti-SOD1 (FL-154, Santa Cruz) antibodies were quantified in the
soluble fraction of the homogenates of ventral and dorsal horn regions of thoractic spinal cord of human samples by sandwich ELISA. The
sandwich ELISA was performed in the absence (−DTT) or presence (+DTT) of pre-treatment of the samples with 10 mM DTT. The SOD1-ALS cases
III-4 and IV-6 and three non-ALS controls (Additional file 1: Table S1) were examined. The averages were shown as bars
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the motor neurons in the ventral horn of the lumbar
spinal cord exhibited immunoreactivity to anti-SOD1int
antibody (Fig. 7c). Again, no immunoreactivity with
anti-SOD1int antibody was observed in the spinal cord/
primary motor cortex of the sporadic ALS cases with
TDP-43 pathologies and also of the non-ALS cases
(Additional file 5: Figure S4B-D).
To reduce the chance of potential conformational
changes of SOD1 during the preparation of sections and
their immunostaining procedures, we prepared soluble
fractions by centrifugation of the homogenates from
either ventral or dorsal horn in the thoractic spinal cords
and then examined those by sandwich ELISA using anti-
SOD1int antibody. ALS associates with degeneration of
motor neurons in the ventral horn with less involvement
of sensory neurons in the dorsal horn of the spinal cord
[33]. As shown in Fig. 7d, the ventral horn of the SOD1-
ALS patients with C111Y mutation (cases III-4 and IV-6;
Additional file 1: Table S1) showed higher signal inten-
sities of anti-SOD1int antibody than those of non-ALS
controls (three cases). In contrast, weak ELISA signals of
anti-SOD1int antibody were detected in the dorsal horn
with almost no difference between the controls and the
ALS patients (Fig. 7d). Also importantly, the ELISA signals
obtained by using anti-SOD1int antibody disappeared
upon pre-treatment of the samples with a reductant, DTT,
suggesting the involvement of disulfide-crosslinks in the
pathological SOD1 species (Fig. 7d). The amounts of total
soluble SOD1 proteins in the ventral and dorsal horns
were not different between the controls and the ALS pa-
tients (Fig. 7e). Collectively, our anti-SOD1int antibody is
considered to detect the disulfide-crosslinked SOD1 oligo-
mers as pathological species in SOD1-ALS patients.
Discussion
SOD1-ALS cases are characterized mainly by abnormal
accumulation of mutant SOD1 proteins in motor neurons
of the affected spinal cords [5], while the pathological in-
volvement of the other types of neurons and glia cells has
been reported [20, 29, 34, 35]. The conformational stabil-
ity of SOD1 is significantly compromised by most of the
mutations [36], which triggers the formation of soluble
oligomers and insoluble aggregates of SOD1 in vitro. In
this study, we successfully prepared anti-SOD1olig/int anti-
bodies exclusively recognizing the disulfide-crosslinked
SOD1 oligomers in vitro and then found that those anti-
bodies detect the pathological SOD1 species in spinal
cords of the SOD1-ALS patients (C111Y) as well as trans-
genic model mice (G1H and loxG37R mice).
Several mechanisms for the formation of disulfide-
crosslinked SOD1 oligomers have been proposed in vitro
[7, 8, 37]. Our epitope analysis of anti-SOD1olig/int anti-
bodies has further revealed the conformation of disul-
fide-crosslinked SOD1 oligomers, in which the regions
usually buried in the native SOD1 are exposed. More pre-
cisely, the epitopes of our antibodies (Gly 44 - Asn 53)
were found to include the protein interior (Gly 44 - Glu
49) and the dimer interface (Phe 50 - Asn 53) in SOD1.
The protein interior and the dimer interface have been
noted as targets for the design of antibodies specifically
recognizing misfolded SOD1 proteins [38]. For example,
the polyclonal antibodies, USOD [16] and AJ10 [39], were
raised against the region covering the protein interior of
the natively folded SOD1 (Leu 42 - His 48 and Val 29 -
Cys 57, respectively) (Fig. 8a), and both antibodies have
been shown to immunostain the pathological inclusions in
the spinal motor neurons of SOD1-ALS patients. Also, the
monoclonal antibodies, C4F6 and D3H5, have been re-
ported to recognize the conformational epitope buried in
the SOD1 native conformation [38, 40–42] and detect
pathological inclusions in SOD1-ALS patients [43, 44].
Because SOD1 forms a very tight homodimer (Kd ~
0.1 nM) [45], furthermore, the dimer interface in the
natively folded conformation is also buried. The polyclonal
antibodies called SEDI and 131–153 Ra-ab were raised
against the peptides containing the dimer-interface region
(SEDI, Arg 143 - Ile 151; 131–153 Ra-ab, Asn 131 - Gln
153; Fig. 8a and b) [28, 46] and again exclusively immuno-
stained the inclusions in the affected spinal motor neu-
rons of SOD1-ALS patients [16, 28, 47–50]. In the
pathological conditions, therefore, SOD1 is supposed to
misfold into a conformation with the exposed structural
interior and the disrupted interface for dimerization.
Depending upon experimental conditions in vitro and
in vivo, nonetheless, SOD1 is known to misfold in dis-
tinct pathways [8–10, 51–54]. Therefore, we could not
exclude the possibility that our antibodies detect certain
misfolded species other than the disulfide-crosslinked
oligomer. It has been known that several misfolded con-
formations of SOD1 can be reproduced in vitro simply
by metal dissociation and/or disulfide reduction. Actu-
ally, we have shown that reduction of the disulfide bond
drastically increases fluctuation of the loops IV and VII
(Fig. 8b), temporarily “peels” those loops off from the β-
barrel scaffold, and thus potentially exposes the epitope
of anti-SOD1int antibody [55]. As shown in Fig. 5b, how-
ever, disulfide-reduced and/or demetallated forms of
SOD1 were not recognized by our anti-SOD1int anti-
body. Therefore, the reversible conformational fluctu-
ation increased by disulfide reduction/demetallation is
probably not sufficient to allow the antibody to access
the epitope buried inside the protein. The disulfide-
reduced and demetallated SOD1 has been shown to irre-
versibly form the amyloid-like aggregates [56], which were
again not recognized by anti-SOD1int antibody (Fig. 5b).
We further examined ELISA to test the reactivities of
anti-SOD1int antibody toward E,E-SOD1S-S and E,E-
SOD1SH that were misfolded/unfolded with either
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guanidine hydrochloride (6 M) or acidic buffer (pH 3.0) in
vitro, but no signals were observed (Additional file 11:
Figure S10A). In sharp contrast, USOD-like and SEDI-like
antibodies were found to react with various non-native
forms of SOD1 proteins (Fig. 5c and d, Additional file 11:
Figure S10B, C, and D). Taken together, those extensive
tests reveal quite high recognition specificity of our anti-
SOD1int antibody toward the disulfide-crosslinked SOD1
oligomer.
Anti-SOD1int antibody detected pathological SOD1
species in vivo, and also, the reductant-sensitive smears
of SOD1 were observed in the Western blots of the af-
fected tissues of model mice (Fig. 6, Additional file 10:
Figure S9). We hence speculate that the disulfide-
crosslinked SOD1 oligomer is involved in the pathology
of SOD1-ALS. Actually, disulfide-crosslinked oligomers
of SOD1 have been reproduced in cultured cells [18, 57].
While the reducing environment of the cytoplasm might
be unfavorable for crosslinking proteins via disulfide
bonds, our preliminary in vitro experiments confirmed
the formation of disulfide-crosslinked SOD1 oligomers in




Fig. 8 A disulfide shuffling mechanism describes exposure of pathological epitope in SOD1. (a) Schematic representation of the epitopes of the
antibodies that exclusively detect the pathological inclusions in SOD1-ALS cases. (b) The regions of the overlapped epitopes among antibodies
specific to pathological SOD1 (Gly 44 - Asn 53, green; Asn 131 - Ile 151, purple) are mapped on the crystal structure of the native SOD1 protein
(PDB ID: 2C9V). Together with the intramolecular disulfide bond (Cys 57 - Cys 146) in yellow, copper and zinc ions are also shown as blue and red
ball models, respectively. (c) Schematic representation of the epitope exposure through the disulfide shuffling mechanism. Cys 57 and 146, which
form the canonical disulfide bond, are shown as “S” in yellow, while the other two free Cys residues, Cys 6 and 111, as S in green. Red curves
represent loops IV and VII. Mutation-induced conformational disorder of SOD1 allows the free Cys (green S) to nucleophilically attack and then
shuffle the Cys 57 - Cys 146 disulfide bond (yellow). The disulfide shuffling within and between SOD1 molecules is considered to peel the loops
(red) off from the structural core of SOD1 and thereby expose the epitope (arrows in red) for our antibodies
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oxidized glutathione (data not shown), which is a feasible
redox condition of the cytoplasm [58]. In our proposed
mechanism for the formation of SOD1 oligomers [8], the
disulfide bond is not newly introduced but rather shuffled
among the Cys residues in SOD1 (Fig. 8c). More specific-
ally, the disulfide shuffling will break the canonical Cys 57
- Cys 146 disulfide bond and detain SOD1 in the mis-
folded conformation where the loops IV and VII are
peeled off from the β-barrel scaffold with the persistent
exposure of the epitope region (Fig. 8c). Such a disulfide
shuffling may be more robust against reducing environ-
ment than de novo formation of disulfide bonds.
We have also shown here that immunoreactivities of
our anti-SOD1olig/int antibodies are quite exclusive to the
human SOD1-ALS cases as well as the transgenic mice
(G1H and loxG37R mice) but not to the controls with-
out SOD1 mutations. Their immunoreactivities were,
furthermore, well correlated with the severity of degen-
eration in the model mice (lumbar spinal cord > cervical
spinal cord > brainstem > cerebellum; Fig. 6a, Additional
file 10: Figure S9A) and in the SOD1-ALS cases (ventral
horn > dorsal horn; Fig. 7d). As described in the Results
section, nonetheless, we should note significant reduc-
tion in the immunoreactivities of anti-SOD1olig/int anti-
bodies toward the G1H mice in the disease end stage
(Figs. 2 and 6a). While such decline will be partly be-
cause of the concomitant loss of motor neurons [24],
mutant SOD1 is also known to accumulate as amyloid-
like aggregates in the spinal cord of the model mice after
the appearance of motor symptoms [9, 15]. Given that
our anti-SOD1int antibody was not able to react with the
amyloid-like SOD1 aggregates in vitro (Fig. 5b), the de-
clined immunoreactivity of anti-SOD1olig/int antibodies
at the end-stage might indicate the formation of
amyloid-like SOD1 aggregates due to quite high expres-
sion of G93A SOD1 proteins in G1H mice.
In contrast, the spinal motor neurons of the SOD1-ALS
patients in their disease end-stage were immunostained
with anti-SOD1olig/int antibodies (Figs. 3 and 7), suggesting
distinct properties of pathological SOD1 species between
G1H mice and the patients. Because the inclusions in
SOD1-ALS patients exhibited no reactivity to an amyloid-
diagnostic dye, Thioflavin-S [16], the amyloid-like SOD1 ag-
gregates would form only in the end-stage G1H mice but
not in human SOD1-ALS cases. While it needs to be tested
whether the SOD1 species detected by our antibodies was
an on-pathway intermediate for the formation of amyloid-
like SOD1 aggregates, the pathologies in the autopsied
human cases might not proceed into the terminal stage as
in the G1H mice at 160 days of age. Compared to the
amyloid-like SOD1 aggregates in the end stage of G1H
mice, we speculate that SOD1 species detected by anti-
SOD1olig/int antibodies in the pre-symptomatic G1H mice
have more significance in the pathogenicity of SOD1-ALS.
It is also important to note moderate immunoreactiv-
ities of anti-SOD1int antibody in the spinal cords of WT
mice at 360 days but not at 150 days of age (Additional file
8: Figure S7A). WT mice do not develop severe motor
phenotypes but show several neuropathological and symp-
tomatic changes in their advanced age including mito-
chondrial vacuolization in spinal cords (>210 days),
impaired motor performance (>410 days), and motor
neuron death (~2 years) [59]. No immunoreactivities of
C4F6 and SEDI antibodies were reported in the spinal
cords of WT mice at 215 and 100 days of age, respectively
[28, 43]. Instead, the immunoreactivity of anti-SOD1int
antibody appears to match with the neuropathological
changes in WT mice and would hence probe the mis-
folded SOD1 proteins with toxicity toward motor neu-
rons. Involvement of wild-type SOD1 proteins in the
ALS pathogenesis still remains controversial [60], and
no immunostaining by anti-SOD1int antibody was con-
firmed in our sporadic ALS cases without SOD1 mutations
(Additional file 5: Figure S4C and D). Nonetheless, we
speculate that SOD1 could become toxic to motor neurons
by assuming the anti-SOD1olig/int antibody-positive con-
formation such as the disulfide-crosslinked oligomers even
in the absence of any pathogenic mutations.
Conclusions
In summary, we successfully prepared the antibodies ex-
clusively recognizing the disulfide-crosslinked SOD1
oligomers in vitro. Pathological SOD1 species in the af-
fected tissues of SOD1-ALS patients as well as trans-
genic mice provided the immunological epitope to those
antibodies. While it is possible that the epitope of our
antibodies becomes available upon misfolding of SOD1
through some other mechanisms, we propose that the
oligomerization via shuffling of the disulfide bond has
pathological significance in SOD1-ALS.
Additional files
Additional file 1: Table S1. Information on human cases examined in
this study. (PDF 49 kb)
Additional file 2: Figure S1. Preparation of soluble disulfide-crosslinked
SOD1 oligomers in vitro. E,E-SOD1S-S (100 μM) was incubated in the NNE
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Additional file 3: Figure S2. Specificity of anti-SOD1olig antibody for
immunohistochemical examination of mouse spinal cords. The sections
of lumbar spinal cords of (A, B) a non-transgenic mouse (C57BL/6) at
200 days of age and (C, D) a G1H mouse at 100 days of age were stained
with anti-SOD1olig antibody. For the absorption experiments shown in (C,
D), the anti-SOD1olig antibody was pre-absorbed on ice for 5 h with ei-
ther (C) soluble disulfide-crosslinked SOD1(A4V) oligomers (6.7 μM in
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monomer base) or (D) E,Zn-SOD1S-S (6.7 μM). Nuclei were also counter-
stained with hematoxylin (blue). (PDF 265 kb)
Additional file 4: Figure S3. Immunohistochemical examination on
lumbar spinal cords of G1H mice with anti-SOD1 antibody. The sections
of lumbar spinal cords of G1H mice at (A) 60, (B) 100, (C) 140, and (D)
160 days of age were stained with monoclonal anti-SOD1 (clone 1G2,
MBL) antibody. The images in the low magnification are shown in the left
panel, where the region enclosed with a broken line is magnified and
shown in the right panel. Nuclei were counterstained with hematoxylin
(blue). The bar in each panel represents 100 μm (left panel) and 50 μm
(right panel). (PDF 273 kb)
Additional file 5: Figure S4. Representative images for
immunohistochemical examination of non SOD1-ALS cases. Spinal cord
sections of (A) non-ALS (C1 in Additional file 1: Table S1), (B) non-ALS (C3
in Additional file 1: Table S1), (C) sporadic ALS (sALS3 in Additional file 1:
Table S1), and (D) sporadic ALS (sALS4 in Additional file 1: Table S1) cases
were immunostained with either (A) anti-SOD1olig or (B-D) anti-SOD1int
antibody. Nuclei were also stained by hematoxylin (blue). The bars repre-
sent 50 μm. (PDF 1002 kb)
Additional file 6: Figure S5. Equal fixation of various forms of SOD1
proteins on the ELISA plate. Amounts of SOD1 proteins fixed on the
ELISA plates for the experiments in Fig. 5 were quantified by indirect
ELISA with polyclonal anti-SOD1 antibody (FL-154, Santa Cruz Biotechnol-
ogy). Amounts of SOD1 in the plates for experiments in Fig. 5a were
shown in the panel (A), while those in Fig. 5b, c, and d were in the panel
(B). The ELISA signal was represented as a ratio against that obtained
using BSA. Three independent experiments were performed to estimate
error bars (standard deviation). No statistically significant difference in the
ELISA signal was confirmed among the in vitro samples examined. (PDF
52 kb)
Additional file 7: Figure S6. Epitope analysis on USOD-like and SEDI-
like antibodies by indirect ELISA. The peptides were prepared as a fusion
protein with an N-terminal 6x His tagged GST and adsorbed on an ELISA
plate. SOD1 species recognized by (A) USOD-like and (B) SEDI-like anti-
bodies were quantified as ELISA signals that were represented as a ratio
against those of BSA. Almost equal amounts of peptides were adsorbed
on the plate, which was confirmed by an ELISA using anti-GST antibody
(C). Three independent experiments were performed to estimate error
bars (standard deviation). (PDF 29 kb)
Additional file 8: Figure S7. Anti-SOD1int antibody specifically detects
pathological SOD1 in spinal cords of ALS-model mice. (A, B) SOD1 spe-
cies recognized by (A) anti-SOD1int and (B) anti-SOD1 (FL-154, Santa
Cruz Biotechnology) antibody were quantified in the soluble fraction of
the homogenates of lumbar spinal cords of non-transgenic (nonTG),
WT, and G1H mice by sandwich ELISA. The data on G1H mice at 30 days
of age are the same with those in Fig. 6a and b and shown here again
for comparison. (C, D) Sandwich ELISA with (C) anti-SOD1int and (D)
anti-SOD1 (FL-154, Santa Cruz Biotechnology) antibody was examined
by using the soluble fraction of the homogenates of lumbar spinal
cords of G1H mice. The samples were pre-treated with 10 mM DTT for
reducing disulfide bonds. In all panels, three independent mouse sam-
ples were examined to estimate error bars (standard deviation), and the
statistical analysis has been performed to obtain the P values indicated
in the figures. (PDF 47 kb)
Additional file 9: Figure S8. Examination of soluble SOD1 disulfide-
crosslinked oligomers in cerebellum and brainstem of ALS-model mice.
(A) Cerebellum and (B) brainstem of non-transgenic (NTG) and G1H mice
and (C) cerebellum of loxG37R mice were homogenized in the presence
of 100 mM iodoacetamide and 1% NP-40 and centrifuged at 20,000 x g
for 30 min so as to prepare soluble supernatant. The supernatant was
then separated in a polyacrylamide gel by non-reducing SDS-PAGE and
probed by Western blot using anti-SOD1 antibody (FL-154, Santa Cruz
Biotechnology). For comparison, the soluble fraction of the lumbar spinal
cord homogenates of G1H mice at 160 days of age was also loaded on
the same gel. GAPDH was used as a protein loading control for Western
blot. (PDF 812 kb)
Additional file 10: Figure S9. Anti-SOD1int antibody specifically detects
pathological SOD1 in spinal cords of loxG37R mice. (A, B) SOD1 species
recognized by (A) anti-SOD1int and (B) anti-SOD1 (FL-154, Santa Cruz Bio-
technology) antibody were quantified in the soluble fraction of the ho-
mogenates of lumbar spinal cord (red), cervical spinal cord (green),
brainstem (blue), and cerebellum (gray) of loxG37R mice by sandwich
ELISA. Ages of the mouse samples examined are as follows; 100 (three in-
dependent mice), 174 (two independent mice), 188, 374 (three independ-
ent mice), 386, 392, and 445 days of age. The data were divided into two
groups before and after the onset of the disease (350 days of age) and
statistically analyzed by two-tailed student’s t test. The difference in the
signal intensity before and after the disease onset was statistically signifi-
cant in lumbar and cervical spinal cords (**: P < 0.01). (C) Soluble
disulfide-crosslinked SOD1 oligomers in loxG37R mice were examined by
Western blotting. Lumbar spinal cords of loxG37R and G1H mice at indi-
cated days of ages were homogenized in the presence of 100 mM iodoa-
cetamide and 1% NP-40 and centrifuged at 20,000 x g for 30 min so as
to prepare soluble supernatant. In the presence and absence of the redu-
cing reagent, β-ME, the supernatant was then separated in a polyacryl-
amide gel by SDS-PAGE and probed by Western blot using anti-SOD1
antibody (FL-154, Santa Cruz Biotechnology). GAPDH was used as a pro-
tein loading control for Western blot. (PDF 870 kb)
Additional file 11: Figure S10. Reactivity of the antibodies toward
chemically misfolded/unfolded forms of SOD1. E,E-SOD1SH and E,E-
SOD1S-S (100 μM; WT, A4V, G37R, and G85R) were first incubated at room
temperature for two hours either in 50 mM Tris/100 mM NaCl/5 mM
EDTA/6 M guanidine hydrochloride (GdnHCl) at pH 7.4 or in 50 mM
sodium acetate buffer at pH 3.0 and then fixed on an ELISA plate. ELISA
was performed using (A) anti-SOD1int, (B) USOD-like, (C) SEDI-like, and (D)
anti-SOD1 (FL-154, Santa Cruz Biotechnology) antibodies. The ELISA signal
was represented as a ratio against that obtained using BSA. Three inde-
pendent experiments were performed to estimate error bars (standard
deviation). (PDF 49 kb)
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